Abbott’s CardioMEMS Hero PA Pressure Reader Launched in United States

June 9, 2026—Abbott announced on its LinkedIn page that the company’s CardioMEMS Hero device is now available in the United States.

Medtronic’s Symplicity Spyral RDN Treatment Evaluated for Reducing Albuminuria in Renal Disease

June 8, 2026—Medtronic announced that new results from the Global SYMPLICITY Registry DEFINE (GSR DEFINE) demonstrated significant reductions in albuminuria in patients with hypertensive renal disease after treatment with radiofrequency renal denervation (RDN).

Anteris Global PARADIGM Pivotal Trial of DurAVR THV Cleared in France

June 8, 2026—Anteris Technologies Global Corp.

Medtronic’s Harmony Transcatheter Pulmonary Valve to Treat RVOT Evaluated in 5-Year Data

June 4, 2026—Medtronic announced new data on 5-year outcomes with the company’s FDA-approved Harmony transcatheter pulmonary valve (TPV) for treatment of native or surgically repaired right ventricular outflow tract in patients with severe pulmonary regurgitation.

SCCT/SCAI Consensus Statement Standardizes Use of CT-Derived FFR

June 4, 2026—The Society of Cardiovascular Computed Tomography (SCCT) announced that, in collaboration with the Society for Cardiovascular Angiography and Interventions (SCAI), it has released an expert consensus document on the use of coronary CT angiography (CCTA)-derived fractional flow reserve (FFR-CT) for assessing coronary artery disease.

Advanced NanoTherapies Secures Financing for SirPlux Duo DCB Therapy

June 2, 2026—Advanced NanoTherapies, Inc. (ANT), which is developing the SirPlux Duo drug-coated balloon therapy for coronary and peripheral applications, announced the closing of a Series B financing totaling more than $31 million.

ESC Consensus Statement Calls for Women’s Heart Centers to Address Inequality in Diagnosis and Care of Cardiovascular Disease

May 29, 2026—The European Society of Cardiology (ESC) announced the publication of a report asserting that Europe needs dedicated women’s heart centers to address the inequality of cardiovascular care.

4-Year BIOADAPTOR RCT Data Presented for Elixir’s DynamX System 

May 28, 2026—Elixir Medical announced 4-year results from the BIOADAPTOR randomized controlled trial (RCT), which is comparing the company’s DynamX sirolimus-eluting coronary bioadaptor system to a standard-of-care drug-eluting stent (DES).